Cargando…

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy

Diabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to seriou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, Jennifer, Herat, Lakshini, Rooney, Jennifer, Rakoczy, Elizabeth, Schlaich, Markus, Matthews, Vance B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891593/ https://www.ncbi.nlm.nih.gov/pubmed/35234250 http://dx.doi.org/10.1042/BSR20212209

Ejemplares similares

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
por: Herat, Lakshini Y., et al.
Publicado: (2022)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
por: Herat, Lakshini Yasaswi, et al.
Publicado: (2023)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging
por: Matthews, Jennifer R., et al.
Publicado: (2020)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
por: Herat, Lakshini Y, et al.
Publicado: (2020)

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes
por: Agostino, Mark, et al.
Publicado: (2021)

Sympathetic stimulation with norepinephrine may come at a cost
por: Herat, Lakshini Y., et al.
Publicado: (2019)

The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
por: Herat, Lakshini, et al.
Publicado: (2017)

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
por: Magno, Aaron L., et al.
Publicado: (2019)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α
por: Magno, Aaron L., et al.
Publicado: (2020)

Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2021)

The Schlager mouse as a model of altered retinal phenotype
por: Herat, Lakshini Y., et al.
Publicado: (2019)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients
por: Nolde, Janis M., et al.
Publicado: (2020)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension
por: Frost, Shaun, et al.
Publicado: (2021)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
por: Thirunavukarasu, Sharmaine, et al.
Publicado: (2021)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

LBSUN290 A Rare, Sordid Tale Of The Two Most Dreaded Adverse Effects Of SGLT-2 Inhibitors Occurring Concurrently - Acute Pancreatitis And Euglycemic Diabetic Ketoacidosis - Within Days Of Initiating Empagliflozin Therapy.
por: Arora, Gunjan, et al.
Publicado: (2022)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Microvascular changes at different stages of chronic kidney disease
por: Kannenkeril, Dennis, et al.
Publicado: (2020)

A cautionary note for researchers treating mice with the neurotransmitter norepinephrine
por: Matthews, Vance B., et al.
Publicado: (2018)

SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

Plasma phenylalanine and tyrosine and their interactions with diabetic nephropathy for risk of diabetic retinopathy in type 2 diabetes
por: Luo, Hui-Huan, et al.
Publicado: (2020)

A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis
por: Fernandez Felix, Daniel A, et al.
Publicado: (2022)

LBODP062 SGLT2 Inhibition Ameliorates Cognitive And Physical Impairment In Patients With HFpEF And Diabetes
por: Mone, Pasquale, et al.
Publicado: (2022)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i545eu47htken98f1lm6797plv